A new early-stage clinical trial found that a novel monoclonal antibody provided dose-dependent full protection against the ...

The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...

Two types of industrially processed hard fats, widely used in everyday foods such as margarines and baked goods, are unlikely ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...

Taiho Pharmaceutical Co., Ltd. ("Taiho") and Arcus Biosciences, Inc. (NYSE:RCUS, "Arcus") announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International ...

Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study2 Lupus nephritis affects more than 1.7 ...

SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...

October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...